Target intelligence / Profile preview

FLNB antisense RNA 1 (FLNB-AS1)

Target
FLNB-AS1
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01

Overview

FLNB antisense RNA 1 (FLNB-AS1) is a long non-coding RNA transcribed from the opposite DNA strand at the FLNB locus. As a natural antisense transcript, it likely participates in gene expression regulation, mainly via cis mechanisms—affecting transcription, splicing, or chromatin structure in its genetic neighborhood. It is not thought to encode a protein or act as a traditional drug target (receptor or enzyme), but such antisense lncRNAs are increasingly studied for roles in cancer, development, and as possible candidates for RNA-targeting therapeutics (e.g., antisense oligonucleotides). The specific functions and clinical relevance of FLNB-AS1 remain to be fully elucidated, but parallels to other antisense lncRNAs suggest a likely role in fine-tuning FLNB gene expression and possibly contributing to disease phenotypes through regulatory interactions.

Other names
FLNB-AS1FLNB antisense RNA 1 (non-protein coding)FLNB-AS1 (non-protein coding)
02

Mechanism of action

For potential therapeutics: RNase H-mediated degradation of RNA (utilized by ASOs to silence target lncRNAs); Occupancy-only ASOs may also modulate RNA stability, splicing, or translation

03

Biological functions

Regulation of gene expression (primarily cis effects on FLNB, but possibly trans on other loci)Potential modulation of transcription, chromatin structure, and alternative splicing
04

Disease associations

Potential roles in cancer through gene regulation and ceRNA (competing endogenous RNA) mechanismsMay participate in developmental regulation and imprinting, as seen in other antisense RNAs; specific disease links for FLNB-AS1 are largely uncharacterized in current literature
05

Safety considerations

No specific concerns for FLNB-AS1. General challenges with lncRNA targeting include: off-target effects, delivery, and incomplete knowledge of biological functions
06

Interacting drugs

None directly established. However, antisense oligonucleotides (ASOs) can be designed to target lncRNAs like FLNB-AS1
07

Biomarkers

None established for FLNB-AS1 specifically; lncRNAs are under investigation as potential cancer and developmental disorder biomarkers

Beyond the preview

Go deeper on FLNB antisense RNA 1 (FLNB-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLNB antisense RNA 1 (FLNB-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call